UMN trial shows hydroxychloroquine has no benefit over placebo in preventing COVID-19

June 03, 2020

MINNEAPOLIS, MN- June 3, 2020 - Today, University of Minnesota Medical School researchers published the results from the first randomized clinical trial testing hydroxychloroquine for the post-exposure prevention of COVID-19.

The trial results, which were published in the , determined that hydroxychloroquine was not able to prevent the development of COVID-19 any better than a placebo. Further, 40% of trial participants taking hydroxychloroquine developed non-serious side effects -- predominantly nausea, upset stomach or diarrhea. However, the trial found no serious side effects or cardiac complications from taking hydroxychloroquine.

The randomized placebo-controlled trial, which rapidly launched on March 17, tested if hydroxychloroquine could prevent COVID-19 infection in healthy persons after exposure to someone with COVID-19. The trial enrolled 821 non-hospitalized adults from across the U.S. and Canada, who were exposed to COVID-19 from someone living in their same household or as a healthcare worker or first responder. Half of the participants received five days of hydroxychloroquine while the other half received five days of a placebo. The trial was a double-blind trial, meaning that neither the participants nor the researchers knew what the participants received. Participants were followed for two weeks to see who developed symptomatic COVID-19.

Overall, approximately 12% of those given hydroxychloroquine developed COVID-19 versus approximately 14% given the vitamin placebo (folate). This was not a statistical difference, and even if there was a statistical difference, this would equate to treating 42 persons with hydroxychloroquine in order to prevent one infection. There was no further benefit to prevent infection among those who also took zinc or vitamin C.

David Boulware, MD, MPH, the senior investigator of the trial and infectious disease physician at the University of Minnesota, launched the trial with the hope that an inexpensive, widely-available, oral medication could prevent or treat coronavirus early in the disease before people are sick enough to need hospital care.

"Our objective was to answer the question of whether hydroxychloroquine worked to prevent disease or did not work," Boulware said. "While we are disappointed that this did not prevent COVID-19, we are pleased that we were able to provide a conclusive answer. Our objective was to find an answer."
-end-
This trial launched within nine days of beginning the project through the work of a team of University of Minnesota infectious disease physicians from the Medical School - Drs. Matthew Pullen, Sarah Lofgren, Caleb Skipper and Radha Rajasingham; statisticians Ananta Bangdiwala, Nicole Engen and Dr. Kathy Hullsiek from the School of Public Health; Pharmacologist Dr. Melanie Nicol from the College of Pharmacy; among many students, trainees and M Health Fairview investigational pharmacy staff. The trial was in collaboration with McGill University, University of Manitoba and University of Alberta.

About the University of Minnesota Medical School

The University of Minnesota Medical School is at the forefront of learning and discovery, transforming medical care and educating the next generation of physicians. Our graduates and faculty produce high-impact biomedical research and advance the practice of medicine. Visit

University of Minnesota Medical School

Related Minneapolis Articles from Brightsurf:

Minneapolis study finds most major heart attacks occur in people with normal cholesterol
Researchers wanted to find out if new statin guidelines were affecting the number of heart attacks.

During late life, what's important changes
Supportive late life care improves experience and cost, and model can be replicated.

Minneapolis Heart Institute physician receives American College of Cardiology top honor
Cardiologist will receive the Douglas P. Zipes Distinguished Young Scientist Award for his commitment to improving patient care.

New protocols could significantly reduce postoperative setbacks in cardiac patients
MHIF recognized that the occurrence of POAF under traditional surgical protocols was not preventing or reducing the number of POAF patients.

Vascular surgery research brings new options to high-risk stroke patients
More than 300,000 Americans are diagnosed annually with blockages of the carotid artery.

Media advisory: 3,000 insect scientists to meet at Entomology 2015 in Minneapolis
Members of the media are invited to attend Entomology 2015, which will be held Nov.

New blood pressure guidelines may lead to under treatment of older adults
In 2014, the Joint National Committee released the eighth update to the blood pressure guidelines (JNC8P).

Minneapolis Heart Institute Foundation performs first US implant of valve replacement device
Minneapolis Heart Institute Foundation physicians are conducting a research study using the first transcatheter mitral valve replacement in the US The Tendyne Bioprosthetic Mitral Valve is designed to give implanting physicians total control because it is fully repositionable and retrievable which allows physicians to see the outcome before the procedure is closed.

First use of new ablation catheter in US offers improved atrial fibrillation treatment
Dr. Daniel Melby, an investigator at the Minneapolis Heart Institute Foundation, performed the first atrial fibrillation ablation in the US using Biosense Webster's new THERMOCOOL SMARTTOUCH SF contact force sensing catheter as part of an FDA regulated safety trial.

Study finds most older adults qualify for statin therapy under new cholesterol guidelines
According to research published today by Minneapolis Heart Institute Foundation research cardiologist Michael Miedema, M.D., M.P.H., nearly all individuals in their late 60s and early 70s now qualify for a statin medication to reduce their risk of cardiovascular disease under the recently released cholesterol guidelines from the American College of Cardiology and the American Heart Association.

Read More: Minneapolis News and Minneapolis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.